Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Pathology/Molecular Biology

Tumour Site

Presenters

Marion Jaffrelot

Citation

Annals of Oncology (2019) 30 (suppl_5): v797-v815. 10.1093/annonc/mdz269

Authors

M. Jaffrelot1, J. Selves2, N. Fares3, A. Staub4, A.P. Laurenty5, M. DANJOUX2, J. Meilleroux2, E. Chipoulet6, C. Toulas7, R. Guimbaud1

Author affiliations

  • 1 Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 2 Department Of Pathology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, 31059 - Toulouse/FR
  • 3 Haute Garonne, Hospital Rangueil, 31400 - Toulouse/FR
  • 4 Haute Garonne, CH de Montauban, 82013 - Montauban/FR
  • 5 Oncology, Clinique Croix du sud, 31130 - QUINT FONSEGRIVES/FR
  • 6 Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, 31059 - Toulouse/FR
  • 7 Genetics, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, 31059 - Toulouse/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1379

Background

MMR testing is performed to screen Lynch Syndrome, evaluate the prognosis of colorectal cancer (CRC) and predict the efficacy of PD1/PDL1 blockade in all tumor types. Two methods are available: immunohistochemistry (IHC) using antibodies against MMR proteins and molecular biology (MB) for assessing microsatellite instability (MSI). Classically, dMMR tumor corresponds to loss of expression of two proteins (MLH1 and PMS2 or MSH2 and MSH6) associated with MSI. Atypical profiles of dMMR tumors have sporadically been described. The aim of our study was to describe the frequency and characteristics of these atypical cases.

Methods

All MMR testing performed in our center between 2007 and 2017 were checked to select cases with both available IHC and MB. Then, all dMMR cases were reviewed to identify atypical cases which were defined by: isolated loss of expression of one protein, loss of expression of two proteins without MSI, normal expression of the four proteins with MSI, aberrant loss of proteins, or MSI-low. Biological data of atypical cases were controlled and clinical data were collected for each case.

Results

4948 MMR tests were performed, 3800 had both available IHC and MB data, and 585 were dMMR (15 %). Among them, 97 cases were atypical and after biological control, 8 cases were re-classified typical; allowing to finally identify 89 atypical cases: 60 CRC, 10 endometrial carcinoma, 8 digestive non CRC and 11 others types of cancers. A strong correlation with genetic syndromes was observed for those atypical profiles.Table:

2015P

Isolated PMS2 or MSH6 loss n = 53Expression of the four proteins n = 5MSH2/MSH6 or MLH1/PMS2 loss n = 16Aberrant loss of proteins n = 15
MSI433-13
MSI low128-
MSS *9-82
Clinical characteristicsPredominantly CCR Genetic predisposition syndrome (73%)Exclusively CCR or endometrial Genetic predisposition syndrome (≥40%)Predominantly Non CRC (63%)None

(* MSS: microsatellite stability)

Conclusions

Even using controlled IHC and MB, 15% of dMMR tumors have an atypical profile. These atypical cases mainly involve non CRC cancer with a strong prediction for Lynch syndrome. Their therapeutic impact particularly for immunotherapy should be now evaluated.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.